Consensus Veracyte, Inc.

Equities

VCYT

US92337F1075

Market Closed - Nasdaq Other stock markets 04:00:00 2024-07-09 pm EDT			5-day change	1st Jan Change
21.27 ^USD	-1.98%		+0.05%	-22.68%

Jun. 03	Veracyte, Inc. Announces New Afirma Grid Data Suggest Prognostic Ability of Molecular Testing for Thyroid Tumors	CI
May. 07	Earnings Flash (VCYT) VERACYTE Posts Q1 Revenue $96.8M, vs. Street Est of $93.4M	MT

Evolution of the average Target Price on Veracyte, Inc.

Price target over the last 5 years

History of analyst recommendation changes

1b7003bf52e5ca53e0c4e2056.WMtKBTdBQphBo_itrNimKY1-Dm6Qa2e4-5UA4aEcBQk.FflnUkEqds0ey6LqnJfnQLkGa13jDD_MvddW2JhQSF1vnANQcgUFz3XzvQ~9da1b0d909d85a55c91255392443c86b

Analyst Recommendations on Veracyte, Inc.

Goldman Sachs Cuts Veracyte Price Target to $28 From $32, Maintains Buy Rating	Apr. 15	MT
Morgan Stanley Trims Veracyte's Price Target to $21 From $22, Keeps Underweight Rating	Feb. 26	MT
Needham Raises Price Target on Veracyte to $33 From $30, Maintains Buy Rating	Feb. 23	MT
Morgan Stanley Trims Price Target on Veracyte to $22 From $23, Maintains Underweight Rating	Nov. 10	MT
Goldman Sachs Cuts Veracyte's Price Target to $32 From $37, Keeps Buy Rating	23-10-23	MT
Morgan Stanley Adjusts Price Target on Veracyte to $23 From $22, Maintains Underweight Rating	23-08-09	MT
Needham Adjusts Price Target on Veracyte to $35 From $34, Maintains Buy Rating	23-08-09	MT
Needham Adjusts Price Target on Veracyte to $34 From $33, Keeps Buy Rating	23-02-23	MT
Raymond James Downgrades Veracyte to Market Perform From Outperform	23-01-18	MT
Scotiabank Initiates Veracyte at Sector Outperform Rating With $33 Price Target	23-01-05	MT
Scotiabank Initiates Veracyte at Sector Outperform With $33 Price Target	23-01-05	MT
Raymond James Adjusts Price Target on Veracyte to $27 From $31, Maintains Outperform Rating	22-11-04	MT
SVB Securities Adjusts Veracyte's Price Target to $35 From $30, Keeps Outperform Rating	22-11-03	MT
Needham Adjusts Price Target on Veracyte to $33 From $31, Maintains Buy Rating	22-11-03	MT
Raymond James Adjusts Veracyte's Price Target to $31 from $30 Keeps Outperform Rating	22-08-04	MT
Goldman Sachs Cuts Price Target on Veracyte to $32 From $35, Noting Decline in Peer Multiples; Buy Rating Maintained	22-08-04	MT
Needham Adjusts Veracyte's Price Target to $31 From $26, Citing 'Peer Multiple Expansion,' Reiterates Buy Rating	22-08-03	MT
Morgan Stanley Adjusts Veracyte's Price Target to $23 from $25, Keeps Underweight Rating	22-05-04	MT
Raymond James Adjusts Veracyte's Price Target to $30 from $34, Keeps Outperform Rating	22-05-04	MT
Needham Adjusts Veracyte's Price Target to $26 From $31 on Peer Multiple Compression, Reiterates Buy Rating	22-05-04	MT
Needham Adjusts Veracyte's Price Target to $31 From $35, Citing 'Peer Multiple Compression,' Reiterates Buy Rating	22-03-15	MT
Stephens Adjusts Veracyte Price Target to $44 from $52, Keeps Overweight Rating	22-03-02	MT
Lake Street Lowers Veracyte's Price Target to $50 From $95, Maintains Buy Rating	22-03-01	MT
Raymond James Cuts Veracyte's Price Target to $34 From $62, Reiterates Outperform Rating	22-03-01	MT
SVB Leerink Adjusts Veracyte's Price Target to $40 from $45, Maintains Outperform Rating	22-03-01	MT